<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Emerging technologies allow broad profiling of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> genome for differential DNA methylation relative to benign cells </plain></SENT>
<SENT sid="1" pm="."><plain>Herein, <z:chebi fb="0" ids="17137">bisulfite</z:chebi>-modified DNA from lymph nodes with either reactive <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> or follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) were analyzed using a commercial C/UpG genotyping assay </plain></SENT>
<SENT sid="2" pm="."><plain>Two hundred fifty-nine differentially methylated targets (<z:chebi fb="12" ids="28969">DMT</z:chebi>) distributed among 183 unique genes were identified in FL </plain></SENT>
<SENT sid="3" pm="."><plain>Comparison of matched formalin-fixed, paraffin-embedded and frozen surgical pathology replicates showed the complete preservation of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> methylome among differently archived tissue specimens </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of the <z:chebi fb="12" ids="28969">DMT</z:chebi> profile is consistent with a pervasive epigenomic remodeling process in FL that affects predominantly nonlymphoid genes </plain></SENT>
</text></document>